奥马珠单抗治疗慢性自发性荨麻疹的成本效益
本研究采用马尔可夫模型,从社会视角评估奥马珠单抗对比标准治疗(H1抗组胺药最多加量至每日4倍)在荷兰治疗慢性自发性荨麻疹的成本效益。奥马珠单抗相比标准治疗的增量成本效益比为每获得1个质量调整生命年17502欧元;若不计生产力成本,该比值为每质量调整生命年85310欧元。结论认为奥马珠单抗相比标准治疗具有成本效益,该结果被用于将奥马珠单抗确立为荷兰慢性自发性荨麻疹治疗指南的三线疗法。
要点
- 奥马珠单抗对比标准治疗的增量成本效益比为每质量调整生命年17502欧元。
- 不计生产力成本时,增量成本效益比为每质量调整生命年85310欧元。
- 研究结果支持将奥马珠单抗作为荷兰慢性自发性荨麻疹指南的三线治疗。
核心结论
- 奥马珠单抗相比标准治疗具有成本效益,该结果被用于将奥马珠单抗确立为荷兰慢性自发性荨麻疹治疗指南的三线疗法。
研究设计与样本
- 研究采用马尔可夫模型,包含基于7天荨麻疹活动评分的5个健康状态,从社会视角评估奥马珠单抗对比标准治疗在荷兰的成本效益。
- 模型设置和荷兰患者人群特征基于临床专家在线调查并在专家委员会会议上验证,转移概率来自GLACIAL试验。
- 医疗资源使用、生活质量(采用EuroQol-5D)和生产力损失来自93名荷兰患者的疾病负担研究(ASSURE-CSU),医疗资源使用和生产力损失采用荷兰成本手册评估。
- 对照治疗为标准治疗,即(加量)抗组胺药,时间跨度为10年。
主要发现
- 奥马珠单抗对比标准治疗的增量成本效益比为每获得1个质量调整生命年17502欧元。
- 生产力成本对增量成本效益比的价值有重要影响,不计生产力成本时增量成本效益比为每质量调整生命年85310欧元。
临床怎么用
- 研究结果被用于将奥马珠单抗确立为荷兰慢性自发性荨麻疹治疗指南的三线疗法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic spontaneous urticaria (CSU) is a skin disease with itchy hives and/or angio-oedema that last for at least 6 weeks without an obvious external trigger. OBJECTIVES: To determine the cost-effectiveness of omalizumab relative to standard of care (SoC; up to four times the daily dose of H1 -antihistamines) in the Netherlands from a societal perspective. METHODS: The Markov model used consisted of five health states based on Urticaria Activity Score over 7 days. Model settings and characteristics of the Dutch patient population were based on an online survey among clinical experts and were validated during an expert committee meeting. Transition probabilities were derived from the GLACIAL trial. Healthcare consumption, quality of life (using EuroQol-5D) and productivity losses were derived from a burden-of-illness study (ASSURE-CSU) among 93 Dutch patients. Healthcare consumption and productivity losses were evaluated using the Dutch costing manual. The comparator treatment was SoC, consisting of (updosed) antihistamines. A 10-year time horizon was used. RESULTS: The incremental cost-effectiveness ratio (ICER) of omalizumab vs. SoC was €17 502 per quality-adjusted life-year (QALY) gained. Productivity costs played an important role in the value of the ICER; discarding productivity costs resulted in an ICER of €85 310 per QALY. CONCLUSIONS: Omalizumab is cost-effective compared with SoC. The outcomes of this study were used to establish omalizumab as third-line therapy in the Dutch treatment guidelines for CSU.
引用
- Kanters TA, Thio HB, Hakkaart L, et al. Cost-effectiveness of omalizumab for the treatment of chronic spontaneous urticaria. Br J Dermatol. 2018. PMID: 29476533. doi:10.1111/bjd.16476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。